• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

POLA2 在肝细胞癌中的生物学功能。

The Biological Function of POLA2 in Hepatocellular Carcinoma.

机构信息

Dalian Medical University, Dalian, Liaoning, 116000, China.

Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, China.

出版信息

Comb Chem High Throughput Screen. 2024;27(12):1758-1775. doi: 10.2174/0113862073254083231002052550.

DOI:10.2174/0113862073254083231002052550
PMID:37861044
Abstract

INTRODUCTION

The role and prognostic value of POLA2 in liver cancer were comprehensively analyzed through TCGA, GEO, and ICGC databases, and the role of POLA2 in liver cancer cells and the regulatory mechanism involved were further verified through cell experiments. Hepatocellular carcinoma (HCC) is the most prevalent malignancy with high morbidity and mortality. Consequently, it is critical to identify robust and reliable predictive biomarkers and therapeutic targets for HCC patients. POLA2 is involved in the regulation of various tumors, but the specific role of POLA2 in HCC has not been reported. The regulatory role and prognostic value of POLA2 in HCC were determined by bioinformatics techniques and cell experiments.

METHODS

The specific role and prognostic value of POLA2 in HCC were comprehensively analyzed by combining the expression data of POLA2 in TCGA, GEO, and ICGC databases and clinical data. In clinical samples, the expression of POLA2 in liver cancer was verified by QPCR. Further, the regulatory role of POLA2 in HCC was explored through cell experiments such as CCK-8, clonal formation experiment, EDU cell proliferation experiment, and flow cytometry. In terms of mechanism exploration, western blot was used to verify the specific regulatory mechanism that POLA2 participated in. Finally, the relationship between POLA2 and immune invasion of HCC was analyzed by using the TIMER database.

RESULTS

A POLA2 expression and prognosis analysis of HCC patients was conducted using the TCGA, GEO, and ICGC databases. We hypothesized that POLA2 might be one of the key factors contributing to the HCC progression. According to a combined analysis of TCGA, ICGC, and GEO databases, POLA2 was highly expressed in HCC. This was further confirmed in clinical samples using the qPCR. POLA2 knockdown was also performed in vitro on HCC cell lines to study the changes in their biological behavior. We confirmed that POLA2 was associated with HCC proliferation by CCK-8, Colony Formation, and EDU assay. We verified the POLA2's involvement in cell cycle regulation using flow techniques. The relationship between POLA2 and PI3K/AKT/mTOR pathway was explored using Western Blotting experiments regarding its mechanism. Further analysis revealed that the POLA2 expression was significantly associated with HCC immune infiltration.

CONCLUSION

Our study demonstrated POLA2's importance in HCC development and progression and its potential role as a biomarker for disease progression on multiple levels. POLA2 has an important role in regulating the cell cycle and cell proliferation. By interfering with the cell cycle and proliferation, HCC cell growth is inhibited. Furthermore, POLA2 expression was significantly associated with immune infiltration. POLA2 may play a role in HCC immunotherapy based on its correlation with several immune cell types' genetic markers. The findings of this study are expected to lead to new anticancer strategies for HCC.

摘要

简介

本研究通过 TCGA、GEO 和 ICGC 数据库全面分析了 POLA2 在肝癌中的作用和预后价值,并通过细胞实验进一步验证了 POLA2 在肝癌细胞中的作用及其涉及的调节机制。肝细胞癌(HCC)是发病率和死亡率最高的最常见恶性肿瘤。因此,识别 HCC 患者稳健可靠的预测生物标志物和治疗靶点至关重要。POLA2 参与多种肿瘤的调节,但 POLA2 在 HCC 中的具体作用尚未报道。本研究通过生物信息学技术和细胞实验确定了 POLA2 在 HCC 中的调节作用和预后价值。

方法

通过结合 TCGA、GEO 和 ICGC 数据库中 POLA2 的表达数据和临床数据,综合分析 POLA2 在 HCC 中的特定作用和预后价值。在临床样本中,通过 QPCR 验证 POLA2 在肝癌中的表达。进一步通过 CCK-8、克隆形成实验、EDU 细胞增殖实验和流式细胞术等细胞实验探索 POLA2 在 HCC 中的调节作用。在机制探索方面,使用 Western blot 验证 POLA2 参与的具体调节机制。最后,通过 TIMER 数据库分析 POLA2 与 HCC 免疫浸润的关系。

结果

通过 TCGA、GEO 和 ICGC 数据库对 HCC 患者的 POLA2 表达和预后进行分析。我们假设 POLA2 可能是 HCC 进展的关键因素之一。根据 TCGA、ICGC 和 GEO 数据库的综合分析,POLA2 在 HCC 中高表达。通过 qPCR 在临床样本中进一步证实了这一点。还在 HCC 细胞系上进行了体外 POLA2 敲低实验,以研究其生物学行为的变化。我们通过 CCK-8、集落形成和 EDU 测定证实了 POLA2 与 HCC 增殖有关。我们通过流式技术验证了 POLA2 参与细胞周期调控。通过 Western Blotting 实验探讨了其机制,探索了 POLA2 与 PI3K/AKT/mTOR 通路的关系。进一步分析表明,POLA2 的表达与 HCC 免疫浸润有显著相关性。

结论

本研究从多个层面证实了 POLA2 在 HCC 发生和发展中的重要作用及其作为疾病进展标志物的潜力。POLA2 在调节细胞周期和细胞增殖方面具有重要作用。通过干扰细胞周期和增殖,抑制 HCC 细胞生长。此外,POLA2 的表达与免疫浸润显著相关。基于其与几种免疫细胞类型遗传标志物的相关性,POLA2 可能在 HCC 免疫治疗中发挥作用。本研究的发现有望为 HCC 提供新的抗癌策略。

相似文献

1
The Biological Function of POLA2 in Hepatocellular Carcinoma.POLA2 在肝细胞癌中的生物学功能。
Comb Chem High Throughput Screen. 2024;27(12):1758-1775. doi: 10.2174/0113862073254083231002052550.
2
E2F-mediated POLA2 upregulation is correlated with macrophage infiltration and poor prognosis in hepatocellular carcinoma.E2F介导的POLA2上调与肝细胞癌中的巨噬细胞浸润及不良预后相关。
Transl Cancer Res. 2024 Apr 30;13(4):1848-1860. doi: 10.21037/tcr-23-2145. Epub 2024 Apr 19.
3
Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis.POLA2在肝细胞癌中的过表达与免疫浸润有关,并预示着预后不良。
Cancer Cell Int. 2023 Jul 14;23(1):138. doi: 10.1186/s12935-023-02949-z.
4
PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.PSMD9 通过与 c-Cbl 相互作用激活 EGFR 信号转导和循环来促进肝细胞癌的恶性进展。
J Exp Clin Cancer Res. 2024 May 14;43(1):142. doi: 10.1186/s13046-024-03062-3.
5
Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.PI3K/AKT 的激活参与了 TINAG 介导的促进肝癌细胞增殖、侵袭和迁移。
Cancer Biomark. 2018;23(1):33-43. doi: 10.3233/CBM-181277.
6
Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.自噬相关基因RAB7A参与肝细胞癌的免疫调节和恶性进展。
Comput Biol Med. 2023 May;158:106862. doi: 10.1016/j.compbiomed.2023.106862. Epub 2023 Apr 6.
7
A Predictive Model Based on the FBXO Family Reveals the Significance of Cyclin F in Hepatocellular Carcinoma.基于FBXO家族的预测模型揭示了细胞周期蛋白F在肝细胞癌中的意义。
Front Biosci (Landmark Ed). 2024 May 24;29(5):202. doi: 10.31083/j.fbl2905202.
8
The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma.DBF4 锌指在肝细胞癌中的预后意义及其潜在机制。
Sci Rep. 2024 May 9;14(1):10662. doi: 10.1038/s41598-024-60342-w.
9
Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.LAGE3 与 HCC 不良预后相关,并通过 PI3K/AKT/mTOR 和 Ras/RAF/MAPK 通路促进肿瘤发展。
BMC Cancer. 2022 Mar 21;22(1):298. doi: 10.1186/s12885-022-09398-3.
10
MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma.微小 RNA-1468 通过激活 PPAR-γ 介导的 AKT 信号通路促进人肝癌的肿瘤进展。
J Exp Clin Cancer Res. 2018 Mar 6;37(1):49. doi: 10.1186/s13046-018-0717-3.

引用本文的文献

1
A-to-I RNA edited POLA2 attains carcinogenesis in prostatic cancer by impeding immune infiltration and upregulating BTBD7.A到I RNA编辑的POLA2通过阻碍免疫浸润和上调BTBD7在前列腺癌中实现致癌作用。
Discov Oncol. 2025 May 14;16(1):759. doi: 10.1007/s12672-025-02449-8.
2
CEP55: Implications for Immunotherapy and Survival in Hepatocellular Carcinoma.CEP55:对肝细胞癌免疫治疗和生存的影响
Comb Chem High Throughput Screen. 2024 Jun 6. doi: 10.2174/0113862073298525240522104104.
3
E2F-mediated POLA2 upregulation is correlated with macrophage infiltration and poor prognosis in hepatocellular carcinoma.

本文引用的文献

1
Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation.专为医学研究量身定制的基于网络的生存分析工具(KMplot):开发与应用
J Med Internet Res. 2021 Jul 26;23(7):e27633. doi: 10.2196/27633.
2
The ever-increasing importance of cancer as a leading cause of premature death worldwide.癌症作为全球范围内导致过早死亡的主要原因,其重要性日益增加。
Cancer. 2021 Aug 15;127(16):3029-3030. doi: 10.1002/cncr.33587. Epub 2021 Jun 4.
3
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
E2F介导的POLA2上调与肝细胞癌中的巨噬细胞浸润及不良预后相关。
Transl Cancer Res. 2024 Apr 30;13(4):1848-1860. doi: 10.21037/tcr-23-2145. Epub 2024 Apr 19.
肝癌肿瘤免疫微环境与免疫抑制治疗:综述。
Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.肝细胞癌的病因:特别关注脂肪性肝病
Front Oncol. 2020 Nov 30;10:601710. doi: 10.3389/fonc.2020.601710. eCollection 2020.
6
Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌中的生物标志物:现状与未来展望
Biomedicines. 2020 Dec 7;8(12):576. doi: 10.3390/biomedicines8120576.
7
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.肝癌的免疫生物学和免疫治疗:聚焦先天和先天样免疫细胞。
Cell Mol Immunol. 2021 Jan;18(1):112-127. doi: 10.1038/s41423-020-00572-w. Epub 2020 Nov 24.
8
Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead.将基因组学整合到肝细胞癌的临床实践中:未来的挑战。
Am J Gastroenterol. 2020 Dec;115(12):1960-1969. doi: 10.14309/ajg.0000000000000843.
9
DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer.DNA聚合酶α亚基B是非小细胞肺癌中厄洛替尼耐药的结合蛋白。
Cancers (Basel). 2020 Sep 13;12(9):2613. doi: 10.3390/cancers12092613.
10
Involvement of POLA2 in Double Strand Break Repair and Genotoxic Stress.POLA2 在双链断裂修复和遗传毒性应激中的作用。
Int J Mol Sci. 2020 Jun 15;21(12):4245. doi: 10.3390/ijms21124245.